. 2017 Jul 18;9(7):766. doi: 10.3390/nu9070766

Table 4.

The effect of different doses of 50% ME on NAFLD.

Parameters	NC	HFD	HFD + 50% ME
Parameters	NC	HFD	1000 mg/kg	500 mg/kg	250 mg/kg
Liver/body weight (%)	2.69 ± 0.21 ^b	5.80 ± 0.11^d	4.22 ± 0.37 ^a	4.98 ± 0.12	4.79 ± 0.11
Visceral fat/body weight (%)	0.86 ± 0.10 ^b	1.69 ± 0.16 ^d	0.82 ± 0.08 ^b	1.36 ± 0.07	1.32 ± 0.12
Glucose (mmol/L)	4.60 ± 0.27 ^a	5.42 ± 0.26 ^c	4.54 ± 0.11 ^b	4.68 ± 0.10 ^a	4.80 ± 0.10
TC (mmol/L)	1.64 ± 0.09 ^b	7.06 ± 0.85 ^d	4.18 ± 0.39 ^b	4.64 ± 0.54 ^b,c	4.76 ± 0.82 ^b,c
LDL (mmol/L)	0.41 ± 0.02 ^b	5.92 ± 0.81 ^d	3.11 ± 0.34 ^b	3.53 ± 0.49 ^b,c	3.84 ± 3.84 ^a,d
LDL/HDL	0.42 ± 0.03 ^b	6.79 ± 0.57 ^d	3.27 ± 0.34 ^a	3.83 ± 0.45	4.54 ± 0.49
CRI-I = TC/HDL	1.66 ± 0.05 ^b	7.40 ± 0.66 ^d	4.38 ± 0.26 ^b	5.26 ± 0.54 ^a,d	5.76 ± 0.50 ^a,d
CRI-II = LDL/HDL	0.42 ± 0.03 ^b	6.79 ± 0.57 ^d	3.27 ± 0.34 ^a	3.83 ± 0.45	4.54 ± 0.49
AC = (TC − HDL)/HDL	0.65 ± 0.06 ^b	6.99 ± 0.58 ^d	3.37 ± 0.25 ^a	4.27 ± 0.56	6.47 ± 0.73 ^d
ALP (IU/L)	230.60 ± 20.18 ^a	558.20 ± 34.75 ^c	301.00 ± 9.54 ^a	316.60 ± 21.76 ^a	431.00 ± 35.05
ALT (IU/L)	67.20 ± 5.32 ^b	107.80 ± 12.68 ^d	65.60 ± 5.90 ^b	70.60 ± 1.44 ^b	59.40 ± 2.18 ^b
AST/ALT	2.39 ± 0.17^a	1.31 ± 0.11 ^c	2.32 ± 0.29 ^a	2.17 ± 0.08 ^a	2.23 ± 0.09 ^a
Insulin (mU/L)	13.40 ± 0.74 ^b	44.67 ± 1.06 ^d	14.86 ± 0.84 ^b	15.34 ± 0.64 ^b	19.26 ± 1.23 ^b
HOMA-IR	2.73 ± 0.19 ^b	10.90 ± 0.41 ^d	2.99 ± 0.16 ^b	3.19 ± 0.16 ^b	4.10 ± 0.23 ^b
Steatosis	0.00 ± 0.00 ^b	3.00 ± 0.00 ^d	1.20 ± 0.20 ^b	1.40 ± 0.24 ^a	1.80 ± 0.20
Lobular inflammation	0.00 ± 0.00 ^b	2.00 ± 0.00 ^d	1.00 ± 0.00 ^a	1.20 ± 0.20	1.20 ± 0.20
Hepatocyte ballooning	0.00 ± 0.00 ^b	2.00 ± 0.00	2.00 ± 0.00	2.00 ± 0.00	2.00 ± 0.00
NAS	0.00 ± 0.00 ^b	7.00 ± 0.00 ^d	4.20 ± 0.20 ^a,c	4.60 ± 0.24 ^d	5.20 ± 0.37 ^d

Results are expressed as mean ± SEM, compared to HFD group. ^a p < 0.05 vs. HFD group; ^b p < 0.01 vs. HFD group; ^c p < 0.05 vs. normal group; ^d p < 0.01 vs. normal group.